Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms.

Abstract

BACKGROUND:

Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis.

METHODS:

We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques.

RESULTS:

26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p < 0.001) and 53% of adenomas (p < 0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027).

CONCLUSION:

Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.

• Authors: M Tobi, J Hatfield, V Adsay, K Galagan, R Kozarek, M Inagaki, S Kasai, Y Tokusashi, T Obara, R H Hruban, J Lough, A N Barkun, M Jabbari, R Sheikh, B Ruebner, M J Lawson, E Ben-Josef, S Fligiel
• Journal: International journal of pancreatology : official journal of the International Association of Pancreatology (Int J Pancreatol) Vol. 29 Issue 3 Pg. 141-50 ( 2001) ISSN: 0169-4197 [Print] United States
• PMID: 12067217 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Antibodies, Monoclonal
• Defensins

Topics

• Adenocarcinoma, Mucinous (metabolism, pathology)
• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal
• Defensins (metabolism)
• Female
• Humans
• Immunohistochemistry
• Male
• Middle Aged
• Pancreatic Neoplasms (metabolism, pathology)
• Prognosis